Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts.
IPO Year: 2000
Exchange: NASDAQ
Website: translate.bio
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/4/2021 | $45.00 → $38.00 | Neutral | Roth Capital |
8/3/2021 | $19.00 → $38.00 | Market Perform | SVB Leerink |
8/3/2021 | Outperform → Market Perform | William Blair | |
7/26/2021 | $28.00 → $45.00 | Buy | Roth Capital |
4 - Telesis Bio Inc. (0001850079) (Issuer)
4 - Telesis Bio Inc. (0001850079) (Issuer)
4 - Telesis Bio Inc. (0001850079) (Issuer)
4 - Telesis Bio Inc. (0001850079) (Issuer)
4 - Telesis Bio Inc. (0001850079) (Issuer)
3 - Telesis Bio Inc. (0001850079) (Issuer)
3 - Telesis Bio Inc. (0001850079) (Issuer)
3 - Telesis Bio Inc. (0001850079) (Issuer)
3 - Telesis Bio Inc. (0001850079) (Issuer)
3 - Telesis Bio Inc. (0001850079) (Issuer)
SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)
SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)
SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)
SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)
SC 13D/A - Translate Bio, Inc. (0001693415) (Subject)
SC 13G/A - Translate Bio, Inc. (0001693415) (Subject)
SC 13D - Translate Bio, Inc. (0001693415) (Subject)
SC 13D - Translate Bio, Inc. (0001693415) (Subject)
SC 13G/A - Translate Bio, Inc. (0001693415) (Subject)
SC 13G/A - Translate Bio, Inc. (0001693415) (Subject)
8-K - Telesis Bio Inc. (0001850079) (Filer)
8-K - Telesis Bio Inc. (0001850079) (Filer)
10-Q - Telesis Bio Inc. (0001850079) (Filer)
8-K - Telesis Bio Inc. (0001850079) (Filer)
8-K - Telesis Bio Inc. (0001850079) (Filer)
8-K - Telesis Bio Inc. (0001850079) (Filer)
10-Q - Telesis Bio Inc. (0001850079) (Filer)
8-K - Telesis Bio Inc. (0001850079) (Filer)
8-K - Telesis Bio Inc. (0001850079) (Filer)
ARS - Telesis Bio Inc. (0001850079) (Filer)
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, today announced financial results for the second quarter and first half of 2024. Highlights Gibson SOLA – the Company continues to advance its Gibson SOLA reagent platform that enables on-premises automated overnight synthesis of high-fidelity long DNA and mRNA on a variety of liquid handling platforms. The Company's presentation "Enhancing Therapeutic Protein Production with Gibson SOLA Enzymatic DNA Assembly: Pioneeri
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas
SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial Officer, effective August 28, 2023. As CFO, Kullback will be responsible for the Company's financial planning and analysis, accounting, internal audit, tax, and treasury functions. "Bill's deep industry knowledge, operational expertise, and extensive financial experience make him ideally positioned to help lead us through the next phase of the Company's growth," said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. "We are thrilled to welcome Bill to our team and excited to have another lead
-- 20 years of combined industry, medical and academic expertise in pulmonary and rare disease to support continued advancement of mRNA therapeutic pipeline -- LEXINGTON, Mass., March 22, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced that Rand Sutherland, MD, MPH, has been appointed President effective March 22, 2021, Dr. Sutherland's first day of employment. Dr. Sutherland brings 20 years of combined industry, medical and academic expertise in pulmonary and rare diseases to this role. His most recent industry experience includes strategic and operational direction of Global Medical Affairs at Sanofi G
CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Wren Therapeutics Ltd., (“Wren”), a biopharmaceutical company pioneering a unique network kinetics approach to drug discovery for protein misfolding diseases, today announced the closing of a £12.4 million (c. $17.0 million) financing. This financing brings the total capital raised to date to approximately £33 million (c. $45 million). The financing was led by existing shareholder The Baupost Group, with participation from existing investors including LifeForce Capital and new investors including Schooner Capital and Industry Ventures. Dr. Samuel Cohen, Chief Executive Officer of Wren, commented: “This support from both our existing as
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, today announced financial results for the second quarter and first half of 2024. Highlights Gibson SOLA – the Company continues to advance its Gibson SOLA reagent platform that enables on-premises automated overnight synthesis of high-fidelity long DNA and mRNA on a variety of liquid handling platforms. The Company's presentation "Enhancing Therapeutic Protein Production with Gibson SOLA Enzymatic DNA Assembly: Pioneeri
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the first quarter of 2024. In discussing results, recently appointed President and CEO Eric Esser said, "I am pleased with our performance as we execute against our strategy to focus on Gibson SOLA and BioXp mRNA solutions. Our BioXp mRNA offerings continue to gain traction and are delivering real improvements in speed and simplicity to our customers in their discovery workflows. I'm also excited abo
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (the Company) (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced that it will effect a 1-for-18 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on Thursday, May 9, 2024, and the Company's common stock will open for trading on The Nasdaq Global Select Market on May 9, 2024 on a post-split basis, under the existing ticker symbol "TBIO" but with a new CUSIP number 192003200. The reverse stock split is part of the Compa
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated benchtop DNA and mRNA synthesis solutions, today announced a focus in strategy enabled by the commercial availability of its groundbreaking Gibson SOLA platform. Going forward, the company will increasingly concentrate its efforts on expanding the adoption of Gibson SOLA for both DNA and mRNA high throughput drug discovery applications and will specifically target the BioXp automation platform on mRNA synthesis, where the Company believes it has a highly differentiated offering with significant advantages over existing solutions. The Company believes that its Gibson SOLA platform, an indust
SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023. Results highlight strong BioXp® kit sales, expanding gross margin and reduced operating expense. In discussing the results, Todd R. Nelson Ph.D., Founder and CEO of Telesis Bio said, "I'm pleased with our operating execution in a challenging macro environment during 2023. Our company experienced record BioXp kits sales and expanding gross margin aga
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible and rapid automated synthesis in their own lab, today announced certain preliminary, unaudited financial results for the fourth quarter and year ended December 31, 2023. The results are subject to the completion of the Company's year-end financial reporting processes, reviews, and audit. BioXp® kit revenue for the fourth quarter of 2023 is expected to exceed $1.0 million, the highest level in the history of the Company and an increase of 59.6% from the prior quarter and 25.9% compared to
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023. "This quarter, we continued to drive adoption of our instruments and kits, make progress against important collaborations, advance our mRNA strategy, and strengthen both our Board of Directors and Management Team," said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. Highlights Strengthened board of directors and management team: Appointed Greg Herrema, Senior Advisor to Novalis LifeSciences to the Telesis Bio board of directors in October 2023. Mr. Herrema's distinguished car
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2023 financial results on Monday, November 13, 2023, after the market closes. The press release can be accessed via the Investor section of Telesis Bio's website at https://ir.telesisbio.com/. About Telesis BioTelesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity's greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Teles
SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the commercial release of its BioXp® De novo Cloning and Amplification kit on the BioXp 3250 and BioXp 9600 systems. This cell-free DNA amplification kit provides an efficient automated solution for building and amplifying DNA constructs to transfection-scale quantities in researchers' labs by skipping tedious bacterial scale-up and eliminating unpredictable service provider delivery times. The new kit will provide a robust and reliable solution to progress from sequence to functional screening in days instead of weeks, empowe
Roth Capital reiterated coverage of Translate Bio with a rating of Neutral and set a new price target of $38.00 from $45.00 previously
SVB Leerink reiterated coverage of Translate Bio with a rating of Market Perform and set a new price target of $38.00 from $19.00 previously
William Blair downgraded Translate Bio from Outperform to Market Perform
Roth Capital reiterated coverage of Translate Bio with a rating of Buy and set a new price target of $45.00 from $28.00 previously
SVB Leerink reiterated coverage of Translate Bio with a rating of Market Perform and set a new price target of $19.00 from $18.00 previously
SVB Leerink downgraded Translate Bio from Outperform to Mkt Perform
SVB Leerink downgraded Translate Bio from Outperform to Market Perform and set a new price target of $18.00 from $21.00 previously
Roth Capital reiterated coverage of Translate Bio with a rating of Buy and set a new price target of $28.00 from $37.00 previously
HC Wainwright & Co. reiterated coverage of Translate Bio with a rating of Buy and set a new price target of $28.00 from $32.00 previously
SVB Leerink reiterated coverage of Translate Bio with a rating of Outperform and set a new price target of $21.00 from $33.00 previously
Shares of Conagra Brands, Inc. (NYSE:CAG) fell during Thursday's session after the company reported worse-than-expected fourth-quarter sales results and issued FY25 adjusted EPS guidance below estimates. The company reported adjusted earnings per share of 61 cents, beating the analyst consensus estimate of 57 cents. Quarterly revenues of $2.905 billion missed the street view of $2.930 billion, according to data from Benzinga Pro. Conagra Brands shares declined 3.9% to $27.70 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Kazia Therapeutics Limited (NASDAQ:KZIA) shares surged 88.6% to $1.26. Kazia Therapeutics, on Wednesday, announced result
Gainers Longeveron (NASDAQ:LGVN) shares rose 112.1% to $1.74 during Wednesday's regular session. The market value of their outstanding shares is at $11.0 million. vTv Therapeutics (NASDAQ:VTVT) stock increased by 43.09% to $26.0. The market value of their outstanding shares is at $63.2 million. Avidity Biosciences (NASDAQ:RNA) shares increased by 32.32% to $38.27. The company's market cap stands at $3.6 billion. Cyclerion Therapeutics (NASDAQ:CYCN) stock rose 30.39% to $2.96. The company's market cap stands at $7.3 million. Telesis Bio (NASDAQ:TBIO) stock moved upwards by 22.53% to $3.86. The company's market cap stands at $6.4 million. Autonomix Medical (NASDAQ:AMIX) stock rose 20.94%
Telesis Bio (NASDAQ:TBIO) reported quarterly losses of $(5.52) per share which missed the analyst consensus estimate of $(0.23) by 2300 percent. The company reported quarterly sales of $3.440 million which missed the analyst consensus estimate of $6.900 million by 50.14 percent. This is a 45.54 percent decrease over sales of $6.316 million the same period last year.
Telesis Bio Inc. (the Company) (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced that it will effect a 1-for-18 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on Thursday, May 9, 2024, and the Company's common stock will open for trading on The Nasdaq Global Select Market on May 9, 2024 on a post-split basis, under the existing ticker symbol "TBIO" but with a new CUSIP number 192003200. The reverse stock split is part of the Company's plan to regain compliance with the minimu
Gainers Tevogen Bio Holdings (NASDAQ:TVGN) shares rose 51.8% to $1.29 during Thursday's after-market session. The company's market cap stands at $212.3 million. Fresh2 Group (NASDAQ:FRES) stock rose 10.61% to $0.64. The company's market cap stands at $15.6 million. ResMed (NYSE:RMD) stock rose 6.85% to $196.0. The market value of their outstanding shares is at $28.8 billion. The company's, Q3 earnings came out today. MSP Recovery (NASDAQ:LIFW) shares increased by 5.51% to $0.99. The market value of their outstanding shares is at $15.6 million. Gossamer Bio (NASDAQ:GOSS) stock increased by 4.99% to $0.7. The market value of their outstanding shares is at $158.6 million. Telesis Bio (NAS
Gainers Acrivon Therapeutics (NASDAQ:ACRV) stock rose 12.3% to $10.67 during Wednesday's after-market session. The market value of their outstanding shares is at $329.4 million. Amarin Corp (NASDAQ:AMRN) stock moved upwards by 8.12% to $0.95. The company's market cap stands at $381.2 million. Universe Pharmaceuticals (NASDAQ:UPC) stock rose 7.47% to $2.3. The market value of their outstanding shares is at $8.3 million. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) shares moved upwards by 7.14% to $0.34. Telesis Bio (NASDAQ:TBIO) shares moved upwards by 7.12% to $0.34. The company's market cap stands at $10.3 million. Aesthetic Medical Intl (NASDAQ:AIH) shares moved upwards by 6.
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the first quarter of 2024. In discussing results, recently appointed President and CEO Eric Esser said, "I am pleased with our performance as we execute against our strategy to focus on Gibson SOLA and BioXp mRNA solutions. Our BioXp mRNA offerings continue to gain traction and are delivering real improvements in speed and simplicity to our customers in their discovery workflows. I'm also excited abo
SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023. Results highlight strong BioXp® kit sales, expanding gross margin and reduced operating expense. In discussing the results, Todd R. Nelson Ph.D., Founder and CEO of Telesis Bio said, "I'm pleased with our operating execution in a challenging macro environment during 2023. Our company experienced record BioXp kits sales and expanding gross margin aga
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023. "This quarter, we continued to drive adoption of our instruments and kits, make progress against important collaborations, advance our mRNA strategy, and strengthen both our Board of Directors and Management Team," said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. Highlights Strengthened board of directors and management team: Appointed Greg Herrema, Senior Advisor to Novalis LifeSciences to the Telesis Bio board of directors in October 2023. Mr. Herrema's distinguished car
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2023 financial results on Monday, November 13, 2023, after the market closes. The press release can be accessed via the Investor section of Telesis Bio's website at https://ir.telesisbio.com/. About Telesis BioTelesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity's greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Teles
SAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the second quarter of 2023. "We achieved important milestones this quarter toward our path to profitability by delivering revenue growth again while expanding gross margins and reducing operating expenses. In addition, we raised capital during the quarter to provide us with additional operating runway," said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. Highlights Strengthened balance sheet and board of directors: Closed a financing that brought in $28 million with the possibility of obtaining an addi
-- Total revenue of $6.3M in 1QFY23 -- BioXp® franchise revenue increased by 28% SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the first quarter of 2023. "We are pleased with our company's performance this quarter where we delivered 28% growth year over year in BioXp franchise revenue while improving gross margins and holding operating expenses steady," said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. "We believe we are still in the early stages of adoption within our targeted workflows and our value proposition to researchers will continue to in
SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its first quarter 2023 financial results on Thursday, May 11, 2023, after the market closes. In conjunction with the release, management will host a conference call on Thursday, May 11, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of Telesis Bio's website at https://ir.telesisbio.com/. The conference call can be accessed by registering at this link: https://r
-- Record revenue of $9.5M in 4QFY22; Increase of 208% over 4QFY21 -- BioXp® Revenue increased by 158% to $3.4M, in 4QFY22 over 4QFY21 SAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided financial guidance for 2023. "We are grateful to our Telesis Bio team for their tremendous efforts which resulted in strong performance in 2022 when we exceeded our revenue expectations, delivered meaningful expansion of gross margin due to favorable product mix and cost stabilization, delivered key products for
SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023, after the market closes. In conjunction with the release, management will host a conference call on Tuesday, March 21, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of Telesis Bio's website at https://ir.telesisbio.com/. The conference call can be accessed by registering at thi